{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:51:03Z","timestamp":1762005063693,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13023-019-1027-3","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T06:03:18Z","timestamp":1550469798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["An online survey on burden of illness among families with post-stem cell transplant mucopolysaccharidosis type I children in the United States"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0919-6578","authenticated-orcid":false,"given":"Therese","family":"Conner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Rascati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Rangel-Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"issue":"2","key":"1027_CR1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jpeds.2013.01.031","volume":"163","author":"CR Scott","year":"2013","unstructured":"Scott CR, Elliot S, Buroker N, et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr. 2013;163(2):498\u2013503.","journal-title":"J Pediatr"},{"key":"1027_CR2","volume-title":"The Online Metabolic and Molecular Bases of Inherited Disease","author":"EF Neufeld","year":"2014","unstructured":"Neufeld EF, Muenzer J. The Mucopolysaccharidoses. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, editors. The Online Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2014."},{"issue":"10","key":"1027_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/gim.2014.25","volume":"16","author":"M Beck","year":"2014","unstructured":"Beck M, Arn P, Giugliani R, et al. The natural history of MPS I: global perspectives from the MPS I registry. Genet Med. 2014;16(10):759\u201365.","journal-title":"Genet Med"},{"unstructured":"Clarke L. Mucopolysaccharidosis Type I. In: Pagon RA, Adam MP, Ardinger HH, et al. GeneReviews. Seattle: University of Washington, Seattle; 1993-2018. Available from: URL: \n                    https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1162\/\n                    \n                  . Accessed 28 Nov 2018.","key":"1027_CR4"},{"issue":"4","key":"1027_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/01.GIM.0000078027.83236.49","volume":"5","author":"NJ Terlato","year":"2003","unstructured":"Terlato NJ, Cox GF. Can mucopolysaccharidosis type I disease severity be predicted based on a patient\u2019s genotype? A comprehensive review of the literature. Genet Med. 2003;5(4):286\u201394.","journal-title":"Genet Med"},{"issue":"7","key":"1027_CR6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1080\/08035250510031584","volume":"94","author":"S Vijay","year":"2005","unstructured":"Vijay S, Wraith JE. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr. 2005;94(7):872\u20137.","journal-title":"Acta Paediatr"},{"doi-asserted-by":"publisher","unstructured":"Rodgers NJ, Kaizer AM, Miller WP, Rudser KD, Orchard PJ, Braunlin EA. Mortality after hematopoietic stem cell transplantation for severe mucopolysaccharidosis type I: the 30-year University of Minnesota experience. J Inherit Metab Dis 2017;40(2):271\u2013280. doi: \n                    https:\/\/doi.org\/10.1007\/s10545-016-0006-2\n                    \n                  . Epub 2017 Jan 4.","key":"1027_CR7","DOI":"10.1007\/s10545-016-0006-2"},{"key":"1027_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10545-017-0034-6","volume":"40","author":"SH Lum","year":"2017","unstructured":"Lum SH, Stephen KM, Ghosh A, et al. Long term survival and cardiopulmonary outcome in children with hurler syndrome after haematopoietic stem cell transplantation. J Inherit Metab Dis. 2017;40:455\u201360.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"1027_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/sj.bmt.1703839","volume":"31","author":"C Peters","year":"2003","unstructured":"Peters C, Steward CG. National Marrow Donor Program; international bone marrow transplant registry; working party on inborn errors, European bone marrow transplant group. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant. 2003;31(4):229\u201339.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"1027_CR10","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/sj.bmt.1704105","volume":"31","author":"S G","year":"2003","unstructured":"G S, Guffon N, Maire I, Pujol M, Taylor P, Sevin F, et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant. 2003;31(12):1105\u201317.","journal-title":"Bone Marrow Transplant"},{"key":"1027_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1750-1172-3-24","volume":"3","author":"D Moore","year":"2008","unstructured":"Moore D, Connock MJ, Wraith E, et al. The prevalence of and survival in mucopolysaccharidosis I: hurler, hurler-Scheie and Scheie syndromes in the UK. Orphanet J Rare Dis. 2008;3:24.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"1027_CR12","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0002-9149(01)01999-3","volume":"88","author":"EA Braunlin","year":"2001","unstructured":"Braunlin EA, Rose AG, Hopwood JJ, Candel RD, Krivit W. Coronary artery patency following long-term successful engraftment 14 years after bone marrow transplantation in the hurler syndrome. Am J Cardiol. 2001;88(9):1075\u20137.","journal-title":"Am J Cardiol"},{"key":"1027_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/8904_2015_521","volume":"29","author":"AS Kunin-Batson","year":"2016","unstructured":"Kunin-Batson AS, Shapiro EG, Rudser KD, Lavery CA, Bjoraker KJ, Jones SA, et al. Long-term cognitive and functional outcomes in children with Mucopolysaccharidosis (MPS)-IH (hurler syndrome) treated with hematopoietic cell transplantation. JIMD Rep. 2016;29:95\u2013102.","journal-title":"JIMD Rep"},{"key":"1027_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13023-015-0255-4","volume":"10","author":"AR Pal","year":"2015","unstructured":"Pal AR, Langereis EJ, Saif MA, Mercer J, Church HJ, Tyler KL, et al. Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome. Orphanet J Rare Dis. 2015;10:42.","journal-title":"Orphanet J Rare Dis."},{"issue":"1\u20132","key":"1027_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ymgme.2015.06.002","volume":"116","author":"EG Shapiro","year":"2015","unstructured":"Shapiro EG, Nestrasil I, Rudser K, et al. Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment. Mol Genet Metab. 2015;116(1\u20132):61\u20138.","journal-title":"Mol Genet Metab"},{"key":"1027_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/1750-1172-8-155","volume":"8","author":"EJ Langereis","year":"2013","unstructured":"Langereis EJ, Borgo A, Crushell E, Harmatz PR, van Hasselt PM, Jones SA, et al. Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure. Orphanet J Rare Dis. 2013;8:155.","journal-title":"Orphanet J Rare Dis."},{"key":"1027_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1750-1172-6-55","volume":"6","author":"MH Ru de","year":"2011","unstructured":"de Ru MH, Boelens JJ, Das AM, et al. Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011;6:55.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1027_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","volume":"90","author":"M Sifuentes","year":"2007","unstructured":"Sifuentes M, Doroshow R, Hoft R, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007;90(2):171\u201380.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"1027_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144(5):581\u20138.","journal-title":"J Pediatr"},{"issue":"1","key":"1027_CR20","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007;120(1):e37\u201346.","journal-title":"Pediatrics"},{"key":"1027_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1750-1172-8-22","volume":"8","author":"M Anderson","year":"2013","unstructured":"Anderson M, Elliott EJ, Zurynski YA. Australian families living with rare disease: experiences of diagnosis, health services use and needs for psychosocial support. Orphanet J Rare Dis. 2013;8:22.","journal-title":"Orphanet J Rare Dis"},{"key":"1027_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13023-015-0259-0","volume":"10","author":"N Guffon","year":"2015","unstructured":"Guffon N, Heron B, Chabrol B, Feillet F, Montauban V, Valayannopoulos V. Diagnosis, quality of life, and treatment of patients with hunter syndrome in the French healthcare system: a retrospective observational study. Orphanet J Rare Dis. 2015;10:43.","journal-title":"Orphanet J Rare Dis"},{"issue":"24","key":"1027_CR23","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1182\/bloodadvances.2017011387","volume":"1","author":"M Aldenhoven","year":"2017","unstructured":"Aldenhoven M, van den Broek BTA, Wynn RF, O\u2019Meara A, Veys P, Rovelli A, et al. Quality of life of hurler syndrome patients after successful hematopoietic stem cell transplantation. Blood Adv. 2017;1(24):2236\u201342.","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"1027_CR24","first-page":"S89","volume":"17","author":"M Pentek","year":"2017","unstructured":"Pentek M, Gulacsi L, Brodszky V, Baji P, Boncz I, et al. Social\/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. Eur J Health Econ. 2017;17(Suppl 1):S89\u201398.","journal-title":"Eur J Health Econ"},{"key":"1027_CR25","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/ana.24246","volume":"76","author":"M Poe","year":"2014","unstructured":"Poe M, Chagnon SL, Escolar ML. Early treatment is associated with improved cognition in hurler syndrome. Ann Neurol. 2014;76:747\u201353.","journal-title":"Ann Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1027-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1027-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1027-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T10:35:51Z","timestamp":1582022151000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1027-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1027"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1027-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"assertion":[{"value":"3 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Was received by the Chesapeake IRB. Respondents were required to electronically sign an informed consent form before initiating the survey.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"48"}}